This module explains which types of cancer are treated with immuno-oncological treatments, and also discusses the side effects associated with new immuno-oncological agents.
Use of immuno-oncology
Univadis Oncology eLearning
1. Evan J. Lipson Charles G. Drake: Ipilimumab: an Anti-CTLA-4 Antibody for Metastatic Melanoma; Clin. Cancer Res. 17, Nr. 22, 2011, S. 6958–62.
2. Ribas A et al; Efficacy and Safety of the anti-PD-1 monoclonal antibody mk-3475 in 411 patients with melanoma; J Clin Oncol 2014, 32 (18 Suppl 1): LBA9000
3. Robert C et al; Pembrolizumab versus Ipilimumab in Advanced Melanoma; N Engl J Med April 2015 (online first)
4. Rawyn M Poole et al; Pembrolizumab: First Global Approval; Drugs (2014) 74: 1973-1981
5. Amos S et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011. doi: 10.1182/blood-2011-01-325266.
6. Pardoll DM et al; The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer 2012; 12(4): 252-65; doi: 10.1038/nrc3239
7. Patsoukis N et al; Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation; Science Signal (2012); Vol. 5, Issue 230, p. ra46.
Responsible for the content: © 2015 KWHC GmbH, Alewinstr. 13, 29525 Uelzen (Germany). The image sources can be found at: http://www.kwhc.de/webpage/index.php/oncology-nurses-copyrights.html
50mins - Expert presentations By Centers for Disease Control and Prevention
Zika Virus—What Clinicians Need to Know
Experts from the CDC present a comprehensive overview: Zika Virus-What Clinicians Need to Know, and provide responses to selected questions
9mins - Expert presentations By Vicky Tittle
Dr Vicky Tittle, from 56 Dean Street in London, UK, reviews the reasons to test for HIV, when and how to test and which key populations should receive testing. Specific focus is placed on British guidelines for HIV testing and importance to conduct key initial investigations.
13mins - Expert presentations By Professor David Livermore
Future developments in antimicrobial agents
Professor David Livermore highlights increasing resistance and the major bacterial challenges we face. Beta-lactams, the most widely used antibiotic are losing their efficacy. However, there is hope for antimicorbial agents. Cefiderocol, murepavadin and gepotidacin/zoliflodacin all show promise in replacing spent antibiotics. Further, non-antibiotic approaches and improved molecular diagnostics, while not currently comprehensive, could revolutionise the field.